BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted ...

In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib ...

The FDA has cleared BeOne Medicines’ BCL2 blocker sonrotoclax for the treatment of certain patients with mantle cell lymphoma ...

Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...

BEQALZI™ (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, ...

FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta. The ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

Cleveland Browns owners recently made a large donation for cancer research. Dee Haslam lives daily with a rare blood cancer ...

Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatment Three oral presentations at ASCO highlight rapid acceleration of BeOne's solid tumor pipeline BeOne Medicines ...

Central nervous system (CNS) involvement by CLL is rare. We report a non-treated CLL patient with low-risk factors, but showed leptomeningeal involvement during/after neuroborreliosis and EBV ...